Figure S1



medRxiv preprint doi: https://doi.org/10.1101/2021.02.14.21251704; this version posted March 12, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.14.21251704; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S2

BNT162b2 (Pfizer) vaccinees

Participant No.	Sex	Age range	No. of doses	Time since (days)	
				Dose #1	Dose #2
1	F	60s	×2	53	32
2	F	20s	×2	39	17
3	F	20s	×2	38	17
4	M	30s	×2	36	15
5	M	30s	×2	36	15
6	F	30s	×2	36	15
7	F	30s	×2	36	15
8	M	30s	×2	35	14
9	M	40s	×2	35	14
10	M	30s	×2	35	14
11	F	30s	×2	33	13
12	M	30s	×2	33	12
13	F	40s	×2	32	11
14	F	30s	×2	32	11
15	F	30s	×2	32	11
16	F	20s	×2	32	10
17	F	30s	×2	31	10
18	F	30s	×2	31	9
19	F	30s	×2	30	9
20	M	30s	×2	30	9
21	M	30s	×2	30	9
22	F	20s	×2	30	9
23	M	30s	×2	30	9
24	F	30s	×2	30	8
● 25	M	20s	×2	29	8
26	M	30s	×2	29	8
27	M	30s	×2	28	7
	M	30s	×1	20	-
28	F	30s	×2	28	7
29	F	30s	×2	28	7
30	F	20s	×2	27	7
31	F	50s	×2*	28	5
32	F	30s	×2*	26	5
33	M	20s	×2*	26	5
34	M	30s	×2*	25	5
35	F	30s	×2*	27	4
36	F	30s	×2*	25	4
37	F	20s	×2*	23	2
38	F	20s	×2*	26	1
39	M	30s	×1	32	-
40	M	20s	×1	22	-
41	F	20s	×1	19	-
42	F	20s	×1	12	-
43	M	60s	×1	4	-

mRNA-1273 (Moderna) vaccinees

Participant No.	Sex	Age range	No. of doses	Time since (days)	
				Dose #1	Dose #2
44	M	30s	×2	145	117
45	F	60s	×2	139	111
46	M	20s	×2	135	108
47	M	20s	×2	88	60
48	F	20s	×2	86	59
49	F	50s	×2	54	26
	F	50s	×1	26	-
50	F	50s	×2	52	24
51	F	40s	×2	52	24
	F	40s	×1	29	-
52	F	20s	×2	51	23
	F	20s	×1	23	-
53	M	30s	×2	50	22
	M	30s	×1	22	-
54	M	50s	×2	50	22
55	M	50s	×2	50	21
56	F	30s	×2	49	21
57	F	50s	×2	50	20
58	F	60s	×2	50	20
59	F	40s	×2	51	19
60	F	40s	×2	49	19
61	F	50s	×2	50	18
	F	50s	×1	22	-
62	F	60s	×2	49	18
63	F	50s	×2	47	18
	F	50s	×1	19	-
64	F	60s	×2	46	18
65	F	40s	×2	45	17
66	F	70s	×2	43	15
67	M	30s	×2	48	13
68	F	60s	×2	41	13
69	F	50s	×2	42	12
70	M	20s	×2	41	12
71	F	50s	×2	36	12
● 72	F	30s	×2	40	10
73	M	40s	×2	38	10
74	F	60s	×2	39	8
75	F	60s	×2	37	8
76	M	20s	×2	38	7
77	F	60s	×2	37	7
78	F	20s	×2	37	7
79	F	60s	×2*	34	6
80	F	20s	×2*	33	6
81	M	50s	×2*	18	5
82	F	20s	×2*	38	4
83	M	20s	×2*	35	4
84	M	20s	×2*	35	4
85	M	30s	×2*	35	4
86	F	20s	×2*	35	4
87	M	30s	×1	28	-
● 88	F	30s	×1	27	-
89	F	30s	×1	25	-
90	F	60s	×1	24	-
91	F	20s	×1	21	-
● 92	M	30s	×1	20	-
93	M	40s	×1	16	-
94	M	30s	×1	14	-
95	M	30s	×1	13	-
● 96	F	30s	×1	12	-
● 97	M	20s	×1	12	-
98	F	30s	×1	11	-
99	F	20s	×1	2	-

Figure S2. Characteristics of vaccine recipients, related to Figure 2

The sex and age range of 99 vaccine recipients are presented along with time (in days) after the first and, when applicable, second doses of either the BNT162b2 (*left panel*) or mRNA-1273 (*right panel*) vaccines. Individuals who reported having been diagnosed with or highly suspected to have COVID-19 before vaccination are highlighted with a red circle. For 7 out of the 99 vaccinees, two samples taken, one after the first dose and one after the second dose.

● indicates prior diagnosis or high suspicion of COVID-19

Figure S3



medRxiv preprint doi: https://doi.org/10.1101/2021.02.14.21251704; this version posted March 12, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S4



medRxiv preprint doi: https://doi.org/10.1101/2021.02.14.21251704; this version posted March 12, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .